{"title":"PROFILE: Ashim Mitra","authors":"Jean E. Schelhorn, J. Herbers","doi":"10.1093/oso/9780197512715.003.0008","DOIUrl":null,"url":null,"abstract":"Ashim Mitra was a senior faculty member in the School of Pharmacy at the University of Missouri—Kansas City (UMKC). An expert on treatment of eye diseases, Mitra was a star, attracting substantial funding from the National Institutes of Health, state and nonprofit grants, and industrial funding. He had extensive experience with commercialization, and by 2017 had been a named inventor on 11 issued patents. He also served on the University’s patent committee, which made recommendations about technologies the institution should prioritize for commercialization....","PeriodicalId":235446,"journal":{"name":"Beyond Discovery","volume":"2015 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Beyond Discovery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/oso/9780197512715.003.0008","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
阿西姆·米特拉是密苏里大学堪萨斯城分校药学院的高级教员。作为眼科疾病治疗方面的专家,米特拉是一位明星,吸引了来自美国国立卫生研究院(National Institutes of Health)、州和非营利组织拨款以及行业资金的大量资金。他在商业化方面拥有丰富的经验,截至2017年,他已成为11项已发布专利的指定发明人。他还在该大学的专利委员会任职,该委员会就该机构应优先商业化的技术提出建议....
Ashim Mitra was a senior faculty member in the School of Pharmacy at the University of Missouri—Kansas City (UMKC). An expert on treatment of eye diseases, Mitra was a star, attracting substantial funding from the National Institutes of Health, state and nonprofit grants, and industrial funding. He had extensive experience with commercialization, and by 2017 had been a named inventor on 11 issued patents. He also served on the University’s patent committee, which made recommendations about technologies the institution should prioritize for commercialization....